RhumbLine Advisers
NWBO

RhumbLine Advisers’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

RhumbLine Advisers’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-47,196
Closed -$69K – 3131
2016
Q1 		$69K Buy
47,196
+200
+0.4% +$395 ﹤0.01% 2940
2015
Q4 		$150K Buy
46,996
+4,190
+10% +$20.1K ﹤0.01% 2879
2015
Q3 		$268K Buy
42,806
+921
+2% +$8.61K ﹤0.01% 2624
2015
Q2 		$416K Buy
41,885
+4,190
+11% +$36.7K ﹤0.01% 2454
2015
Q1 		$278K Buy
37,695
+7,950
+27% +$53.5K ﹤0.01% 2655
2014
Q4 		$159K Buy
29,745
+1,025
+4% +$5.25K ﹤0.01% 2871
2014
Q3 		$144K Buy
28,720
+100
+0.3% +$615 ﹤0.01% 2865
2014
Q2 		$192K Buy
+28,620
New +$182K ﹤0.01% 2856

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

RhumbLine Advisers's NWBO Position: Q2 2016 in Review

RhumbLine Advisers sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 47,196 shares — an estimated $69K sold.

RhumbLine Advisers first reported a position in NWBO in Q2 2014 and held it in 8 quarters. The position peaked at $416K in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

  • RhumbLine Advisers reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
  • RhumbLine Advisers sold 47,196 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $69K.
  • RhumbLine Advisers first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 8 quarters.
  • RhumbLine Advisers's Northwest Biotherapeutics, Inc. Common stock position peaked at $416K in Q2 2015.
  • 64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on RhumbLine Advisers's 13F filing for Q2 2016, filed 11 Aug 2016.